Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 8/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.61 |
| ▸ | BCL2A1 | Q16548 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RAD1 | O60671 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | BID | P55957 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15757958 | 0.85 | RAD51 (1.00) | RAD51ALKBH5BCL2A1MAPTKMT2A | |
| SCHEMBL15757929 | 0.85 | RAD51 (0.74) | RAD51ALKBH5BCL2A1MAPTKMT2A | |
| SCHEMBL15437908 | 0.83 | RAD51 (0.71) | RAD51MAPTKMT2AALDH1A1 | |
| SCHEMBL15437867 | 0.83 | RAD51 (0.70) | RAD51BCL2A1MAPTKMT2AALDH1A1 | |
| SCHEMBL15758540 | 0.82 | RAD51 (1.00) | RAD51ALKBH5BCL2A1MAPTKMT2A | |
| SCHEMBL15437731 | 0.82 | RAD51 (0.69) | RAD51MAPTKMT2AALDH1A1ALOX12 | |
| SCHEMBL15758723 | 0.81 | RAD51 (1.00) | RAD51BCL2A1MAPTKMT2ARAD1 | |
| SCHEMBL15758402 | 0.81 | RAD51 (1.00) | RAD51ALKBH5BCL2A1MAPTKMT2A | |
| SCHEMBL10834724 | 0.81 | BCL2A1 (0.69) | RAD51ALKBH5BCL2A1MAPTKMT2A | |
| SCHEMBL15758659 | 0.81 | RAD51 (0.67) | RAD51ALKBH5BCL2A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | THE UNIVERSITY OF CHICAGO (US) | 2021-02-09 | — | — | US | disclosed |
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | THE UNIVERSITY OF CHICAGO (US) | 2021-02-09 | — | — | US | disclosed |
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | RAD51, MRE11, RAD50 | RAD51 1/4885ALKBH5 1567/4885BCL2A1 951/4885 |
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | RAD51, MRE11, RAD50 | RAD51 1/4885ALKBH5 1567/4885BCL2A1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.